PDCD1 and lung carcinoma: Based on this mechanism, anti-VEGR agents in combination with anti–PD-1 monoclonal antibodies have been applied to lung cancer, hepatic cell cancer, and renal cell carcinoma; the combination was considered effective and tolerable, and no unexpected toxicities were observed.